TCL Archive In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs November 27, 1998
TCL Archive CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans. November 5, 2004
TCL Archive Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies June 25, 2010
